An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Oncogenic TRK fusions drive cancer cell proliferation across various tumor types.
• TRK fusions are rare but significant drivers of diverse cancers.
• LOXO-101 is a selective oral inhibitor targeting the TRK kinase family.

Purpose of the Study:

• To evaluate the efficacy of LOXO-101 in preclinical models of TRK-fusion-driven cancers.
• To assess the clinical benefit of LOXO-101 in a patient with a metastatic soft-tissue sarcoma harboring an LMNA-NTRK1 fusion.

Main Methods:

• Preclinical testing of LOXO-101 in TRK-fusion-bearing cancer cell lines and in vivo models.
• In situ proximity ligation assay to detect the LMNA-TRKA fusion oncoprotein.
• Phase I clinical trial (NCT02122913) administration of LOXO-101 to a patient with metastatic soft-tissue sarcoma.

Main Results:

• LOXO-101 demonstrated inhibition of TRK fusion oncoproteins and suppressed cancer cell proliferation in vitro.
• LOXO-101 inhibited tumor growth in preclinical models.
• The patient experienced rapid and substantial tumor regression, improved respiratory function, and normalized plasma tumor markers.

Conclusions:

• TRK fusions are confirmed as oncogenic drivers with clear clinical significance.
• LOXO-101 provides the first clinical evidence of therapeutic benefit from targeting TRK fusions.
• Selective TRK inhibition represents a promising therapeutic strategy for cancers with TRK fusions.